Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.